UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 11, 2002
Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-16005 22-2328609
-------- ------- ----------
(State of incorporation) (Commission File Number) (IRS Employer
Identification No.)
110 Little Falls Road
- ---------------------
Fairfield, NJ 07004
- ------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (973) 882-0860
--------------
N/A
- ---
(Former Name or former address, if changed since last report)
Item 5. Other Events.
On December 11, 2002, the Board of Directors of Unigene Laboratories,
Inc. (the "Company") adopted a stockholder rights plan which provides for the
issuance of common stock purchase rights to the Company's common stockholders of
record as of December 30, 2002, as set forth in the Rights Agreement between the
Company and Registrar and Transfer Company, as Rights Agent, attached hereto as
Exhibit 4.1 and incorporated by reference herein.
Item 7(c). Exhibits.
4.1 Rights Agreement, dated as of December 20, 2002, between Unigene
Laboratories, Inc. and Registrar and Transfer Company, as Rights
Agent, which includes as Exhibit A thereto, the Form of Right
Certificate.
20.1 Press Release of the Company, dated December 12, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
UNIGENE LABORATORIES, INC.
By: /s/ Warren P. Levy
------------------------------
Name: Warren P. Levy
--------------------------
Title: President and Chief
-------------------------
Executive Officer
-------------------------
Dated: December 23, 2002